

DOCKET NO.: 3DP-0544

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Barry A. Springer, et al.

Application No.: 10/785,436

Filing Date: February 23, 2004

For: ANALOGS OF HUMAN BASIC FIBROBLAST GROWTH FACTOR

Confirmation No.:

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

DATE OF DEPOSIT:

6/2/04

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

A handwritten signature in black ink, appearing to read "Andrew T. Serafini".

TYPED NAME: Andrew T. Serafini
REGISTRATION NO.: 41,303

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;

or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- ☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith
- ☐ Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).

EXCEPT THAT:

- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☒ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
- ☒ Copies of references **1 thru 95** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. **09/722,495**, filed **November 28, 2000**.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

There are no listed references which are not in the English language.

Date: 6/2/04


Andrew T. Serafini
Registration No. 41,303

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



Form PTO-1449 Modified		Docket No. 3DP-0544	Application No. 10/785,436
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Barry A. Springer, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date February 23, 2004	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	1	Ago, H. et al., "Crystal Structure of Basic Fibroblast Growth Factor at 1.6 Å Resolution", <i>J. Biochem.</i> , 1991 , 110, 360-363	
	2	Arakawa, T. et al., "Characterization of a Cysteine-Free Analog of Recombinant Human Basic Fibroblast Growth Factor", <i>Biochem. Biophys. Comm.</i> , 1989 , 161(1), 335-341	
	3	Arakawa, T. et al., "The Importance of Arg40 and 45 in the Mitogenic Activity and Structural Stability of Basic Fibroblast Growth Factor-Effects of Acidic Amino Acid Substitutions", <i>J. Prot. Chem.</i> , 1995 , 14(5), 263-274	
	4	Basilico, C. et al., "The FGF Family of Growth Factors and Oncogenes", <i>Adv. Canc. Res.</i> , 1992 , 59, 115-165	
	5	Blaber, M. et al., "X-ray Crystal Structure of Human Acidic Fibroblast Growth Factor", <i>Biochemistry</i> , 1996 , 35(7), 2086-2094	
	6	Bowie, J. et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", <i>Science</i> , 1990 , 247, 1306-1310	
	7	Burgess, W.H. et al., "Possible Dissociation of the Heparin-Binding and Mitogenic Activities of Heparin-Binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-b-Inding Activities by Site-directed Mutagenesis of a Single Lysine Residue", <i>J. Cell. Biol.</i> , 1990 , 111, 2129-2138	
	8	Burgess, W.H. et al., "Structure-function Studies of FGF-1: Dissociation and Partial Reconstitution of Certain of its Biological Activities", <i>Molec. Reprod. Devel.</i> , 1994 , 39: 56-61	
	9	Cheng, H. et al., "Spinal Cord Repair in Adult Paraplegic Rats: Partial Restoration of Hind Limb Function", <i>Science</i> , 1996 , 275, 510-513	
	10	Copeland, R.A. et al., "The Structure of Human Acidic Fibroblast Growth Factor and Its Interaction with Heparin", <i>Arch. Biochem. Biophys.</i> , 1991 , 289(1), 53-61	
EXAMINER		DATE CONSIDERED	



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. 3DP-0544	Application No. 10/785,436
		Applicant Barry A. Springer, et al.	
		Filing Date February 23, 2004	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	11	Cunningham, et al., "High-Resolution Epitope Mapping of hGH-Receptor Interacting by Scanning Mutagenesis", <i>Science</i> , June 1989 , 244, 1081-1085	
	12	Eriksson, A.E. et al., "Three-Dimensional Structure of Human Basic Fibroblast Growth Factor", <i>Proc. Natl. Acad. Sci.</i> , 1991 , 88, 3441-3445	
	13	Eriksson, A.E. et al., "Refinement of the Structure of Human Basic Fibroblast Growth Factor at 1.6 A Resolution and Analysis of Presumed Heparin Binding Sites by Selenate Substitution", <i>Prot. Natl. Sci.</i> , 1993 , 2, 1274-1284	
	14	Faham, S. et al., "Heparin Structure and Interactions with Basic Growth Factor", <i>Science</i> , 1996 , 271, 1116-1120	
	15	Fox, G.M. et al., "Production, Biological Activity and Structure of Recombinant Basic Fibroblast Growth Factor and a Analog with Cysteine Replaced by Serine", <i>J. Biol. Chem.</i> , 1988 , 263(34), 18452-18458	
	16	Friedman, S. et al., "Mutagenesis of the Nuclear Localization Sequence in FGF-1 Alters Protein Stability but not Mitogenic Activity", <i>Biochem. Biophys. Res. Comm.</i> , 1994 , 198(3), 1203-1208	
	17	Harper, J.W. et al., "Reductive Methylation of Lysine Residues in Acidic Fibroblast Growth Factor: Effect on Mitogenic Activity Heparin Affinity", <i>Biochemistry</i> , 1988 , 27, 671-678	
	18	Heath, W.F. et al., "Mutations in the Heparin-Binding Domains of Human Basic Fibroblast Growth Factor Alter its Biological Activity", <i>Biochemistry</i> , 1991 , 30, 5608-5615	
	19	Henderson, B. et al., "Therapeutic Potential f Cytokine Manipulation", <i>TIPS</i> , 1992 , 13, 145-152	
	20	Imamura, T. et al., "Recovery of Mitogenic Activityof a Growth Factor Mutant with a Nuclear Translocation Sequence", <i>Science</i> , 1990 , 249, 1567-1570	
EXAMINER		DATE CONSIDERED	



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. 3DP-0544	Application No. 10/785,436
		Applicant Barry A. Springer, et al.	
		Filing Date February 23, 2004	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	21	International Search Report for PCT/US99/30534, mailed September 1, 2000	
	22	Issachi, A. et al., "A Mutant of Basic Fibroblast Growth Factor that has Lost the Ability to Stimulate Plasminogen Activator Synthesis in Endothelial Cells", <i>Ann. NY Acad. Sci.</i> , 1991 , 638, 369-377	
	23	Isacchi, A. et al., "A Six-Amino Acid Deletion in Basic Fibroblast Growth Factor Dissociates its Mitogenic Activity from its Plasminogen Activator-Inducing Capacity", <i>Proc. Natl. Acad. Sci.</i> , 1991 , 88, 2628-2632	
	24	Kusstatscher, S. et al., "Different Molecular Forms of Basic Fibroblast Growth Factor (bFGF) Accelerate Duodenal Ulcer Healing in Rats", <i>J. Pharmacol. Exp. Ther.</i> , 1995 , 275, 456-461	
	25	Li, L.Y et al., "Diminished Heparin binding of a Basic Fibroblast Growth Factor Mutant is Associated with Reduced Binding, mitogenesis, Plasminogen Activator and in Vitro Angiogenesis", <i>Biochemistry</i> , 1994 , 33, 10999-11007	
	26	Liszewski, K., "Companies Aim Novel Therapeutic Strategies at Dual Nature of Angiogenesis", <i>Gen. Eng. News</i> , May 1, 1997 , 6 pages	
	27	Logan, A. et al., "Transforming Growth Factor- β 1 and Basic Fibroblast Growth Factor in the Injured CNS", <i>TIPS</i> , 1993 , 14, 337-343	
	28	Martin, P. "Wound Healing-Aiming for Perfect Skin Regeneration", <i>Science</i> , 1997 , 276, 75-81	
	29	Ornitz, D.M. et al., "FGF Binding and FGF Receptor Activated by Synthetic Heparan-Derived Di- and Trisaccharides", <i>Science</i> , 1995 , 268, 432-436	
	30	Pantoliano, M.W. et al., "Multivalent Ligand-Receptor Binding Interactions in the Fibroblast Growth Factor System Produce a Cooperative Growth Factor and Heparin Mechanism for Receptor Dimerization", <i>Biochemistry</i> , 1994 , 33, 10229-10248	
EXAMINER		DATE CONSIDERED	



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. 3DP-0544	Application No. 10/785,436
		Applicant Barry A. Springer, et al.	
		Filing Date February 23, 2004	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	31	Presta, M. et al., "Structure-Function Relationship of Basic Fibroblast Growth Factor: Site-Directed Mutagenesis of a Putative Heparin-Binding and Receptor-Binding Region", <i>Biochem. Biophys. Res. Comm</i> , 1992 , 185(3), 1098-1107	
	32	Robinson, C.J. "Growth Factors in Wound Healing", <i>TIBTECH</i> , 1992 , 10, 301-302	
	33	SCIOS Annual Report, "Fiblast: A Special Report, 1996 , 8 pages	
	34	Seddon, A.P. et al., "Engineering of Fibroblast Growth Factor: Alteration of Receptor Binding Specificity", <i>Biochemistry</i> , 1995 , 34, 731-736	
	35	Seno, M. et al., "Carboxyl-Terminal Structure of Basic Fibroblast Growth Factor Significantly Contributes to its affinity for Heparin", <i>Eur. J. Biochem</i> , 1990 , 188, 239-245	
	36	Slavin, J. "The Role of Cytokines in Wound Healing", <i>J. Pathol</i> , 1996 , 178, 5-10	
	37	Springer, B.A. et al., "Identification and Concerted Function of Two Receptor Binding Surfaces on Basic Fibroblast Growth Factor Required for Mitogenesis", <i>J. Biol. Chem.</i> , 1994 , 269(43), 26879-26884	
	38	Ten Dijke, P. et al., "Growth Factors for Wound Healing", <i>Bio/Technology</i> , 1989 , 7, 793-798	
	39	Thompson, L.D. et al., "Energetic Characterization of the Basic Fibroblast Growth Factor-Heparin Interaction: Identification of the Heparin Binding Domain", <i>Biochemistry</i> , 1994 , 33(13), 3831-3840	
	40	Van Brunt, J. et al., "Growth Factors Speed Wound Healing", <i>Bio/Technology</i> , 1988 , 6(1), 25-30	
EXAMINER		DATE CONSIDERED	



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. 3DP-0544	Application No. 10/785,436
		Applicant Barry A. Springer, et al.	
		Filing Date February 23, 2004	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	41	Watson, J. et al., <i>Molecular Biology of the Gene</i> , 1987 , 1, 226-227	
	42	Wong, P. et al., "Analysis of Putative eparin-binding domains of fibroblast Growth Factor-1", <i>J. Biol. Chem.</i> , 1995 , 270(43), 25805-25811	
	43	Young, W., "Spinal Cord Regeneration", <i>Science</i> , 1996 , 273, 451	
	44	Zhang, J. et al., "Three-Dimensional Structure of Human Basic Fibroblast Growth Factor, a Structural Homolog of Interleukin 1 β ", <i>Proc. Natl. Acad. Sci.</i> 1991 , 88, 3446-3450	
	45	Zhu, X. et al., "Structural Studies of the Binding of the Anti-Ulcer Drug Sucroses Octasulfate to Acidic Fibroblast Growth Factor", <i>Structure</i> , 1993 , 1, 27-34	
	46	Zhu, X. , "Three-Dimensional Structures of Acidic and Basic Fibroblast Growth Factors", <i>Science</i> , 1991 , 251, 90-93	
	47	Zhu, H. et al., "Glu-96 of Basic Fibroblast Growth Factor is Essential for High Affinity Receptor Binding", <i>J. Bol. Chem.</i> , 1995 , 270(37), 21869-21874	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. 3DP-0544		Application No. 10/785,436	
				Applicant Barry A. Springer, et al.			
				Filing Date February 23, 2004		Group Not Yet Assigned	
U. S. PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
	48	4,785,079	11/15/88	Gospodarowicz, et al.	530	399	
	49	4,902,782	02/20/90	Gospodarowicz, et al.	530	399	
	50	4,956,455	09/11/90	Esch, et al.	530	399	
	51	4,994,559	02/19/91	Moscatelli, et al.	530	399	
	52	5,026,839	06/25/91	Moscatelli, et al.	536	27	
	53	5,130,418	07/14/92	Thompson, S.A.	530	399	
	54	5,132,408	07/21/92	Baird, et al.	530	399	
	55	5,136,025	08/04/92	Scheuermann, et al.	503	413	
	56	5,143,829	09/01/92	Thompson, et al.	435	69.4	
	57	5,155,214	10/13/92	Baird, et al.	530	399	
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Translation		
					YES	NO	
EXAMINER				DATE CONSIDERED			

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. 3DP-0544		Application No. 10/785,436	
				Applicant Barry A. Springer, et al.			
				Filing Date February 23, 2004		Group Not Yet Assigned	
U. S. PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
	58	5,191,067	03/02/93	Lappi, et al.	530	399	
	59	5,206,354	04/27/93	Seddon, et al.	536	23.5	
	60	5,217,954	06/08/93	Foster, et al.	514	12	
	61	5,252,718	10/12/93	Baid, et al.	530	399	
	62	5,302,702	04/12/94	Seddon, et al.	530	399	
	63	5,310,883	05/10/94	Seddon, et al.	530	399	
	64	5,331,095	07/19/94	Shadle, et al.	530	399	
	65	5,332,804	07/26/94	Florkiewicz, et al.	530	399	
	66	5,348,863	09/20/94	Monsan, et al.	435	68.1	
	67	5,350,836	09/27/94	Kopchick, et al.	530	399	
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Translation		
					YES	NO	
EXAMINER				DATE CONSIDERED			

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. 3DP-0544		Application No. 10/785,436	
				Applicant Barry A. Springer, et al.			
				Filing Date February 23, 2004		Group Not Yet Assigned	
U. S. PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
	68	5,352,589	10/04/94	Bergonzoni, et al.	435	69.4	
	69	5,360,896	11/01/94	Senoo, et al.	530	399	
	70	5,371,206	12/06/94	Seddon, et al.	536	23.5	
	71	5,387,673	02/07/95	Seddon, et al.	530	399	
	72	5,439,818	08/08/95	Fiddes, et al.	435	240.2	
	73	5,459,250	10/17/95	Basilico, et al.	536	23.5	
	74	5,464,774	11/07/95	Baird, et al.	536	23.51	
	75	5,478,804	12/26/95	Calabresi, et al.	514	2	
	76	5,482,929	01/09/96	Fukunaga, et al.	514	12	
	77	5,491,220	02/13/96	Seddon, et al.	530	399	
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Translation		
	78	WO 96/22369	07/25/96	PCT	YES	NO	
EXAMINER				DATE CONSIDERED			

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. 3DP-0544		Application No. 10/785,436	
				Applicant Barry A. Springer, et al.			
				Filing Date February 23, 2004		Group Not Yet Assigned	
U. S. PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
	79	5,514,566	05/07/96	Fiddes, et al.	435	69.1	
	80	5,514,652	05/07/96	Watanuki, et al.	514	12	
	81	5,576,288	11/19/96	Lappi, et al.	514	2	
	82	5,604,293	02/18/97	Fiddes, et al.	530	399	
	83	5,612,211	03/18/97	Wilson, et al.	435	378	
	84	5,614,496	03/25/97	Dunstan, et al.	514	12	
	85	5,656,598	08/12/97	Dunstan, et al.	514	12	
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Translation		
					YES	NO	
	86	EP 0 237 966 A2	09/23/87	EPO			
	87	EP 0 281 822 A2	09/14/88	EPO			
	88	EP 0 363 675 A1	04/18/90	EPO			
	89	EP 0 420 222 A1	04/03/91	EPO			
	90	EP 0 510 662 A1	10/28/92	EPO			
	91	EP 0 281 822 B1	07/20/94	EPO			
	92	WO 90/02800	03/22/90	PCT			
	93	WO 91/09126	06/27/91	PCT			
	94	WO 91/14785	10/03/91	PCT			
	95	WO 95/08630	03/30/95	PCT			
EXAMINER				DATE CONSIDERED			